In a report released today, Peter Lawson from Barclays maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report), with a price target of $1.00. The company’s shares closed
In a report released today, Peter Lawson from Barclays maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report), with a price target of $1.00. The company’s shares closed
In a report released today, Jeffrey Hung from Morgan Stanley maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report), with a price target of $4.00. The company’s shares
Analyst Reni Benjamin from JMP Securities reiterated a Buy rating on Prelude Therapeutics (PRLD – Research Report) and keeping the price target at $7.00. Reni Benjamin has given his Buy
Prelude Therapeutics ( ($PRLD) ) has provided an announcement. Prelude Therapeutics announced its third quarter 2024 financial results, highlighting significant progress in its clinical programs. The company demonstrated clinical proof
“Our third quarter was marked by dedicated execution and the achievement of essential milestones for our lead clinical programs targeting SMARCA2,” stated Kris Vaddi, Chief Executive Officer of Prelude. “We